iSyPeM2 - Nano-Tera 2016

8/18/2019 iSyPeM2 - Nano-Tera 2016

1/33

[email protected]

Administration and monitoring of medical treatments

1

Intelligent Systems for Personalized MedicineISyPeM II


2/33

[email protected]

2


dministration and monitoring of medical treatments


3/33

[email protected]

3


dministration and monitoring of medical treatments


4/33

[email protected]

4

s o medical treatment or which monitoring is highly critical

IV ANTIBIOTIC

I!!"NO"##$%IV%

&$"'

CANC%$ TA$'%T%&T(%$A#I%

time after dose (hrs)

I m

a t i n i b e x p o s u r e

( n g / m l )

#atient

Courtesy of N. Widmer

Syva Rapidest!

"nly#ualitative$%rugconcentrationneeds to be&uanti'ed it

*+, accuracyfor %M


5/33

[email protected]

)

Towards distri*+ted *ioanalytic

IV ANTIBIOTIC

I!!"NO"##$%IV%

&$"'

CANC%$ TA$'%T%&T(%$A#I% iSA- Abbott

.lonitStMicroelectronicscobas! ab0in0a

tube

Roce%iagnostics

Accu0.e1 productlines2Roce %iagnostics

op benc

3and0eld

Physiological parameters, DNA

analysis

s o medical treatment or which monitoring is highly critical


6/33

[email protected]

Reduce volume samplesMonitoring of treatmentis often needed inneborn and cild care

.ompact- a4ordableanalytical systems

Measurement performed atte M%integrated it decisions+pport sotware

Interaction andInteroperability

5ater data for decisionon dosage and enricpopulation data

,

6I".37MI.A/A8A9I.A .3A7857S

6I".37MI.A/A8A9I.A .3A7857S

%AA I87RPR7AI"8 A8% MA8A57M78 .3A7857S



7/33

[email protected]

Affordability of the analytical system

Meet the microsample challenge

-

Abbott :Arcitect ci;0M SeguraM 5eiser


8/33

[email protected]

Affordability of the analytical system

Meet the microsample challenge

0

Abbott :Arcitect ci;0M SeguraM 5eiser

Iy#e! II demonstratoro0cost?ully integrated6ased on 3ig sensitive ?PIA@or1s on capillaries


9/33

[email protected]

Microsample analytics in capillaries

#lasma e1traction rom whole

*lood

9ield outperforms any passive on0cip

metod reported to date2 7xtractionfrom eection2

ttpB//dbs0system2c

Renaud ab

2


10/33

[email protected]

3#IA o To*ramycin perormed in glass

microcapillaries+ared glass capillary

ttpB//dbs0system2c

5// 6m

= < C D ; *= *<

=2*C=

=2*D=

=2*;=

=2


11/33

[email protected]

Lack of availability of ligands for drug

molecules

77

" 6 R A M 9

. I 8

I M A I 8 I 6

A . R " I M H S

• %rugs are small molecules

• ey can ave very di4erent solubility andbiocemical and metabolic caracteristics

• In vivo raised antibody against drugs avepoor anities and in some case are notavailable at all

@e develop in vitro approaces for teselection of ligands for di4erent classes

of drugs


12/33

[email protected]

In vitro selection of aptamers

" 6 R A M 9

. I 8

5uiducci ab

%8A aptamers canbe obtained in afe steps tat arebetter or e&ual toexisting R8A

aptamers

?unctional in serumand proved onpatient samples-meeting te clinical

range

Speci'citydemonstrated

Metod can be

applied to di4erentdrugs

.lin2 Parmac2

: CCTTACCTA''T'TA': )8)8 :''AAT''ATCCACATC:


13/33

[email protected]

Measuring Tobramycin concentration

from serum on a palm-sized devices

5uiducci ab

" 6 R A M 9

. I 8

52 et al2 Analytical .emistry- April


14/33

[email protected]

In vitro selection of antibodies

A . R " I M H S

3einis a

?irst in vitroselection ofantibodiesagainst

acrolimus everperformed

o approaceddeployed tocompetition

assay

Peptidemacrocycles0

based approacfor assays

>0M Segura

74.2 3einis- 6icyclic peptide page display- *=t Peptide erapeutics Symposium-


15/33

[email protected]

D T INT!"!T TI#N

ND M N $MNT

7)


16/33

[email protected]

Drug decision support system

developed by I%y"eM II partners

%iv2 .lin2 Parmac2

9ann oma

8o in use at

.3HK andconnected itM"IS database

argelyoutperformingany existingsupport systems

Kalidation and.linical trials inprogress forcerti'cation andcommercialization

?I grant for start0up creationBttpB//2fondation0't2c

ab Innovation Aard- ausanne


17/33

[email protected]

Meta-analysis approaches to build

population pharmacokinetics models

%iv2 .lin2 Parmac2

Br J Clin Pharmacol. 20!

No"#$%&'()0*0+0

.onsolidation of

population studies for %M

Statistical combinationof independentpopulation studies

I M A I 8

I 6

7 ? A K I R

7 8 L

A M I 8 " 5 9 . " S I % 7 S

7-


18/33

[email protected]

"&" approach for data storage

#+*lishD+*scri*e

## Networ;

Contri*+tor$&B

Contri*+tor$&B

&Bmetadata

&B

E+eryD%1change

&ata

uple+center

Negotiate

Initiator

A7

Cryptographic

!od+le

Anonymi>ation!od+le

$&B

8o centralizedsystem fordata storage

.ontributorscan sareteir data andgetanonymized

data from teoters

:Multi0Agent System for %ynamic %ataAggregation in Medical Researc A2%ubovits1aya- K2 Hrovi- I2 6arba- O2Aberer- M2 I2 Scumacer- in preparation%ubovits1aya- A2 Privacy PreservingInteroperability for PersonalizedMedicine- inB Siss Medical Informatics-Siss Society for Medical Informatics-

Sitzerland-


19/33

[email protected]

#utput and outlook

ore tan *+ peer revieed papers publised (only ISyPeM II)

irst demonstrator is functional

I on going it a Parma company (%ebioparm International)

terest in te diagnostics 'eld

72


20/33

[email protected]

/


21/33

[email protected]

7


22/33

[email protected]

Therapeutic Drug Monitoring Today

Abbott :Arcitect ci;


23/33

[email protected]

'ioanalytical systems for diagnostics

and monitoring

Syva Rapidest!

EMIT (Enyme mu!ti"!ied

immunoassay te#hni$ue)

iSA- Abbott


tube

Roce%iagnostics

Accu0.e1 productlines2Roce %iagnostics

op benc

3and0eld

ysiological parameters- %8A analysis 7R %rug of abuse tests

"nly #ualitative$%rug concentrationneeds to be &uanti'edit *+, accuracy for %M

5


24/33

[email protected]

4


25/33

[email protected]

)

I% " M bli d b d


26/33

[email protected]

I%y"eM( nabling drug-based

therapeutic drug monitoring(

iSA- AbbottAccu0.e1 productlines2Roce %iagnostics

3and0eld

ysiological parameters- %8A analysis

I%y"eM integrated

approach to TDM

e3ealtstandards

%atasecurity

.artridge

it stablereagents

o samplevolume

Supported

Interpretationfor nonspecialists

At te clinicand outside


tube

Roce%iagnostics

op benc

,


27/33

[email protected]

I%y"eM II) #b*ectives

%e&e!o" and demonstrate the feasi'i!ity of in vitro selection te#hni$ues to identify suita'!e

"ro'es for dru mo!e#u!es

A#hie&e microvolume "ro#essin and ana!ysis

%e&e!o" no&e! compact and full!inte"rated assas "ro&in their • Sta'i!ity of mo!e#u!es in #om"!e matri and in "resen#e of sam"!e treatment

reaents• S"e#ifi#ity

• A##ura#y

E$ui" !o#a! #!ini#a! institutions and se!e#ted #a'inets *ith #ertified decision support

sstems for dru dosae• Lare!y out"erformin eistin too!s for usa'i!ity and &a!ue of e!a'oration

a""roa#hes em"!oyed+• Conne#ted *ith !o#a! data'ases, se#ure and #onne#ted in a PP net*or to enri#h

"harma#oineti# data'ases

%evelop a top0benc stand0alone proof0of0conceptdemonstrator for in vitro &uantitative analysis of terapeutic

drug from ole blood2 e consortium is no focusing on antibiotics andimmunosuppressant drugs2

"ur metodology

-

M t t i i t i ti f


28/33

[email protected]

Measurement system) miniaturization of

the assay

. ) c m

/ cm

+orescence #olari>ation Imm+noassay

" 6 R A M

9 . I 8

.ompetitive assay(ig sensitivity)

%esigned for lovolumes (focalized)

?unctional on ells-tested on capillariesand paper

Renaud ab

>0M SeguraM2 PfeiferM2 5eiser

0


29/33

[email protected]

"rogress of demonstrator

IntegratedPartially integrated8ot integrated 2


30/33

[email protected]

'A+, " slides

5/


31/33

[email protected]

EImatini*G

Therape+tic dr+g monitoring (%M) forimatinib as been suggested to impro?eeGcacy- assess compliance- and e?al+atedr+g:dr+g interactionseng et al., herapeutic Drug -onitoring. !&()%'+*$,/eruary 202.


32/33

[email protected]

#$%& for tacrolimus 'DM(urrent status and ne)t steps


33/33

enrico accastelli@epf

5otta K- 6uclin - .sa1a .- @idmer 82 Systematic revie of populationparmaco1inetic analyses

Po"u!ation P. Meta-ana!ysis of Imatini'

P+

P+

P

iSyPeM2 - Nano-Tera 2016

Documents

Transcript of iSyPeM2 - Nano-Tera 2016